Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK287615
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
GSK287615 is an investigational therapeutic protein subunit vaccine developed by GSK for the treatment of chronic hepatitis B virus (HBV) infection. It consists of recombinant hepatitis B surface antigen (HBsAg) formulated with a potent Adjuvant System, typically AS01B, which is designed to stimulate robust cellular immune responses, specifically CD8+ cytotoxic T lymphocytes (CTLs), to overcome immune exhaustion in chronic carriers. The vaccine was primarily developed as the protein-boost component of the heterologous prime-boost regimen GSK3528869A, which also utilized viral vector-based vaccines (ChAd154-HBV and MVA-HBV). The goal of this therapeutic approach was to achieve a functional cure, characterized by sustained HBsAg loss. However, GSK terminated the development of the GSK3528869A regimen in 2023 following a Phase 2 interim analysis that suggested the treatment was unlikely to meet its primary efficacy endpoints.
- Other names
- adjuvanted hepatitis B surface antigen vaccineHBsAg/AS01 vaccinetherapeutic hepatitis B vaccine
Beyond the preview
Go deeper on GSK287615.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK287615.